Skip to main content

Zejula Side Effects

Generic name: niraparib

Medically reviewed by Last updated on Dec 1, 2023.

Note: This document contains side effect information about niraparib. Some dosage forms listed on this page may not apply to the brand name Zejula.

Applies to niraparib: oral tablet.

Serious side effects of Zejula

Along with its needed effects, niraparib (the active ingredient contained in Zejula) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking niraparib:

More common

Less common

Incidence not known

Other side effects of Zejula

Some side effects of niraparib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to niraparib: oral capsule, oral tablet.


The most commonly reported adverse reactions (incidence 20% or greater) were

decreased hemoglobin (85%), decreased platelet count (82%), nausea (74%), decreased white blood cell count (66%), thrombocytopenia (61%), fatigue/asthenia (57%), decreased absolute neutrophil count (53%), anemia (50%), constipation (40%), increased AST (36%), vomiting (34%), abdominal pain/distention (33%), neutropenia (30%), increased ALT (28%), insomnia (27%), headache (26%), decreased appetite (25%), nasopharyngitis (23%), rash (21%), diarrhea (20%), dyspnea (20%), hypertension (20%), and mucositis/stomatitis (20%).[Ref]


Very common (10% or more): Decreased hemoglobin (85%), decreased platelet count (82%), decreased white blood cell count (66%), thrombocytopenia (61%), decreased absolute neutrophil count (53%), anemia (50%), neutropenia (30%), leukopenia (17%)[Ref]


Very common (10% or more): Nausea (74%), constipation (40%), vomiting (34%), abdominal pain/distention (33%), diarrhea (20%), mucositis/stomatitis (20%), dyspepsia (18%), dry mouth (10%)[Ref]


Very common (10% or more): Fatigue/asthenia (57%)

Common (1% to 10%): Peripheral edema[Ref]


Very common (10% or more): Increased AST (36%), Increased ALT (28%), AST/ALT elevation (10%)

Common (1% to 10%): Increased gamma-glutamyl transferase, increased blood alkaline phosphatase[Ref]


Very common (10% or more): Insomnia (27%), anxiety (11%)

Common (1% to 10%): Depression[Ref]

Nervous system

Very common (10% or more): Headache (26%), dizziness (18%), dysgeusia (10%)[Ref]


Very common (10% or more): Decreased appetite (25%)

Common (1% to 10%): Hypokalemia, decreased weight[Ref]


Very common (10% or more): Nasopharyngitis (23%), dyspnea (20%), cough (16%)

Common (1% to 10%): Bronchitis, epistaxis[Ref]


Very common (10% or more): Rash (21%)[Ref]


Very common (10% or more): Hypertension (20%), palpitations (10%)

Common (1% to 10%): Tachycardia

Frequency not reported: Hypertensive crisis[Ref]


Very common (10% or more): Myalgia (19%), back pain (18%), arthralgia (13%)[Ref]


Very common (10% or more): Urinary tract infection (13%)[Ref]


Common (1% to 10%): Conjunctivitis[Ref]


Common (1% to 10%): Increased blood creatinine[Ref]


Uncommon (0.1% to 1%): Myelodysplastic Syndrome/Acute Myeloid Leukemia[Ref]

Frequently asked questions


1. Product Information. Zejula (niraparib). Tesaro Inc. 2017.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.